RT Journal Article
SR Electronic
T1 Phase II Trial of Carboplatin, Paclitaxel Plus Vinorelbine in Non-small Cell Lung Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1333
OP 1336
VO 25
IS 2B
A1 ALEXANDER SCHMITTEL
A1 JAN MICHAEL SIEHL
A1 MANFRED SCHULZE
A1 KARSTEN SCHULZE
A1 ECKHARD THIEL
A1 ULRICH KEILHOLZ
YR 2005
UL http://ar.iiarjournals.org/content/25/2B/1333.abstract
AB Background: Vinorelbine was added to carboplatin plus paclitaxel to determine efficacy and toxicity in non-small cell lung cancer (NSCLC) patients with good performance status. Patients and Methods: Vinorelbine 30 mg/m2 plus paclitaxel 175 mg/m2 plus carboplatin AUC 5 was administered every three weeks for a maximum of 6 cycles. Results: One out of 37 patients had a complete and 12 a partial remission (35% response rate). Six patients (16%) had disease stabilization and 18 (49%) progressed. Grade III or IV neutropenia occurred in 11 (30%) and febrile neutropenia in 6 (16%) patients. Grade III/IV neuropathy was observed in 6 (16%) patients. The median time to progression was 6 months (95% CI 4.0 - 8.0), and median survival 11 months (95% CI 8.3 - 13.7). One- and two-year survival was 41% (95% CI 24 - 58) and 24% (95% CI 8.7 - 39.1), respectively. Conclusion: This triple-chemotherapy combination is feasible. The response rates justify further investigation in similar patient subgroups. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved